Hypocomplementemia during tocilizumab treatment
Abstract. Hypocomplementemia has been reported in patients with rheumatoid arthritis treated with tocilizumab (TCZ), but its long-term consequences are unknown. We assessed the long-term outcome of patients treated with TCZ who developed hypocomplementemia regarding serious bacterial infections or a...
Main Authors: | Amir Bieber, MD, Doron Markovits, MD, PhD, Kohava Toledano, MD, Yonit Tavor, MD, Reuven Mader, MD, Alexandra Balbir-Gurman, MD, Yolanda Braun-Moscovici, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2022-06-01
|
Series: | Medicine |
Online Access: | http://journals.lww.com/10.1097/MD.0000000000029528 |
Similar Items
-
Longitudinally Extensive Transverse Myelitis in a Lupus–Neuromyelitis Optica Overlap
by: Yonit Tavor, et al.
Published: (2021-01-01) -
Hypocomplementemia in systemic sclerosis
by: G. Valentini, et al.
Published: (2011-09-01) -
Hypocomplementemia in systemic sclerosis
by: R. Steele, et al.
Published: (2011-06-01) -
Hypocomplementemia in systemic sclerosis- author reply
by: G. Valentini, et al.
Published: (2011-06-01) -
Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome
by: Amrita Goyal, MD, et al.
Published: (2022-05-01)